PDCD1 and nonpapillary renal cell carcinoma: Immunotherapy represented by immune checkpoint (PD-1, CTLA4) inhibitors has made promising progress in the treatment of ccRCC and can prolong the overall survival (OS) and improve patient prognosis (Atkins and Tannir, 2018).